Goldman Sachs Group Inc. Purchases 61,291 Shares of Inogen, Inc (INGN)

Goldman Sachs Group Inc. increased its position in shares of Inogen, Inc (NASDAQ:INGN) by 91.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,043 shares of the medical technology company’s stock after acquiring an additional 61,291 shares during the period. Goldman Sachs Group Inc. owned approximately 0.62% of Inogen worth $12,217,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new position in Inogen during the first quarter worth about $109,000. Schroder Investment Management Group acquired a new position in Inogen during the second quarter worth about $132,000. Victory Capital Management Inc. grew its holdings in Inogen by 36.1% during the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after acquiring an additional 459 shares during the period. Sei Investments Co. grew its holdings in Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after acquiring an additional 443 shares during the period. Finally, Jane Street Group LLC acquired a new position in Inogen during the first quarter worth about $203,000.

A number of equities analysts recently weighed in on INGN shares. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Needham & Company LLC reissued a “buy” rating and issued a $108.00 price target on shares of Inogen in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reissued a “hold” rating and issued a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $90.80.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/goldman-sachs-group-inc-purchases-61291-shares-of-inogen-inc-ingn.html.

Shares of Inogen, Inc (INGN) traded up 1.165% during midday trading on Friday, reaching $95.995. The company’s stock had a trading volume of 7,002 shares. Inogen, Inc has a 12 month low of $50.24 and a 12 month high of $105.35. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 83.329 and a beta of 0.99. The stock has a 50-day moving average of $98.06 and a 200 day moving average of $91.95.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period in the prior year, the firm posted $0.25 earnings per share. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, analysts predict that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.

In other news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total value of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares of the company’s stock, valued at $715,759.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Alison Bauerlein sold 6,667 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $92.64, for a total value of $617,630.88. Following the completion of the sale, the executive vice president now directly owns 15,000 shares of the company’s stock, valued at $1,389,600. The disclosure for this sale can be found here. Insiders have sold 73,667 shares of company stock valued at $7,041,641 over the last three months. Insiders own 5.31% of the company’s stock.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply